549 related articles for article (PubMed ID: 19863737)
1. Reversal of rocuronium-induced profound neuromuscular block by sugammadex in Duchenne muscular dystrophy.
de Boer HD; van Esmond J; Booij LH; Driessen JJ
Paediatr Anaesth; 2009 Dec; 19(12):1226-8. PubMed ID: 19863737
[TBL] [Abstract][Full Text] [Related]
2. Reversal of rocuronium-induced (1.2 mg/kg) profound neuromuscular block by sugammadex: a multicenter, dose-finding and safety study.
de Boer HD; Driessen JJ; Marcus MA; Kerkkamp H; Heeringa M; Klimek M
Anesthesiology; 2007 Aug; 107(2):239-44. PubMed ID: 17667567
[TBL] [Abstract][Full Text] [Related]
3. Neuromuscular transmission: new concepts and agents.
de Boer HD
J Crit Care; 2009 Mar; 24(1):36-42. PubMed ID: 19272537
[TBL] [Abstract][Full Text] [Related]
4. Rocuronium-induced neuromuscular block and sugammadex in pediatric patient with duchenne muscular dystrophy: A case Report.
Kim JE; Chun HR
Medicine (Baltimore); 2017 Mar; 96(13):e6456. PubMed ID: 28353578
[TBL] [Abstract][Full Text] [Related]
5. Cochrane corner: sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade.
Abrishami A; Ho J; Wong J; Yin L; Chung F
Anesth Analg; 2010 Apr; 110(4):1239. PubMed ID: 20357160
[TBL] [Abstract][Full Text] [Related]
6. Reversal of rocuronium-induced neuromuscular blockade with sugammadex in pediatric and adult surgical patients.
Plaud B; Meretoja O; Hofmockel R; Raft J; Stoddart PA; van Kuijk JH; Hermens Y; Mirakhur RK
Anesthesiology; 2009 Feb; 110(2):284-94. PubMed ID: 19194156
[TBL] [Abstract][Full Text] [Related]
7. Reversal of rocuronium-induced (1.2 mg kg-1) profound neuromuscular block by accidental high dose of sugammadex (40 mg kg-1).
Molina AL; de Boer HD; Klimek M; Heeringa M; Klein J
Br J Anaesth; 2007 May; 98(5):624-7. PubMed ID: 17347184
[TBL] [Abstract][Full Text] [Related]
8. Reversal of profound, high-dose rocuronium-induced neuromuscular blockade by sugammadex at two different time points: an international, multicenter, randomized, dose-finding, safety assessor-blinded, phase II trial.
Pühringer FK; Rex C; Sielenkämper AW; Claudius C; Larsen PB; Prins ME; Eikermann M; Khuenl-Brady KS
Anesthesiology; 2008 Aug; 109(2):188-97. PubMed ID: 18648227
[TBL] [Abstract][Full Text] [Related]
9. Reversal of neuromuscular block with a selective relaxant-binding agent: sugammadex.
Ren WH; Jahr JS
Am J Ther; 2009; 16(4):295-9. PubMed ID: 19535969
[TBL] [Abstract][Full Text] [Related]
10. Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety, and pharmacokinetics.
Sparr HJ; Vermeyen KM; Beaufort AM; Rietbergen H; Proost JH; Saldien V; Velik-Salchner C; Wierda JM
Anesthesiology; 2007 May; 106(5):935-43. PubMed ID: 17457124
[TBL] [Abstract][Full Text] [Related]
11. Sugammadex: the first selective binding reversal agent for neuromuscular block.
Kovac AL
J Clin Anesth; 2009 Sep; 21(6):444-53. PubMed ID: 19833281
[TBL] [Abstract][Full Text] [Related]
12. Sugammadex in clinical practice.
Mirakhur RK
Anaesthesia; 2009 Mar; 64 Suppl 1():45-54. PubMed ID: 19222431
[TBL] [Abstract][Full Text] [Related]
13. The use of sugammadex in a patient with myasthenia gravis.
Unterbuchner C; Fink H; Blobner M
Anaesthesia; 2010 Mar; 65(3):302-5. PubMed ID: 20105151
[TBL] [Abstract][Full Text] [Related]
14. Sugammadex: another milestone in clinical neuromuscular pharmacology.
Naguib M
Anesth Analg; 2007 Mar; 104(3):575-81. PubMed ID: 17312211
[TBL] [Abstract][Full Text] [Related]
15. Reversal of profound rocuronium or vecuronium-induced neuromuscular block with sugammadex in isoflurane-anaesthetised dogs.
Mosing M; Auer U; West E; Jones RS; Hunter JM
Vet J; 2012 Jun; 192(3):467-71. PubMed ID: 22030475
[TBL] [Abstract][Full Text] [Related]
16. The effect of residual neuromuscular blockade on the speed of reversal with sugammadex.
White PF; Tufanogullari B; Sacan O; Pavlin EG; Viegas OJ; Minkowitz HS; Hudson ME
Anesth Analg; 2009 Mar; 108(3):846-51. PubMed ID: 19224792
[TBL] [Abstract][Full Text] [Related]
17. Sugammadex reversal of rocuronium-induced neuromuscular blockade: a comparison with neostigmine-glycopyrrolate and edrophonium-atropine.
Sacan O; White PF; Tufanogullari B; Klein K
Anesth Analg; 2007 Mar; 104(3):569-74. PubMed ID: 17312210
[TBL] [Abstract][Full Text] [Related]
18. Efficacy, safety, and pharmacokinetics of sugammadex for the reversal of rocuronium-induced neuromuscular blockade in elderly patients.
McDonagh DL; Benedict PE; Kovac AL; Drover DR; Brister NW; Morte JB; Monk TG
Anesthesiology; 2011 Feb; 114(2):318-29. PubMed ID: 21239968
[TBL] [Abstract][Full Text] [Related]
19. Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine.
Flockton EA; Mastronardi P; Hunter JM; Gomar C; Mirakhur RK; Aguilera L; Giunta FG; Meistelman C; Prins ME
Br J Anaesth; 2008 May; 100(5):622-30. PubMed ID: 18385265
[TBL] [Abstract][Full Text] [Related]
20. Sugammadex: a selective relaxant binding agent for reversal of neuromuscular block.
Hogg RM; Mirakhur RK
Expert Rev Neurother; 2009 May; 9(5):599-608. PubMed ID: 19402771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
